Summit, a biotech spin-out from Oxford University, has received £2.4m ($3.18m) for trials into treatment of Duchene muscular dystrophy (DMD) as part of the UK’s £26m Biomedical Catalyst Fund. The funding is a turn of fortunes for the struggling Didcot-based spin-out, which saw its headcount axed from 40 to 13 during the UK’s recession. It…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
